BiomedicalPublications

Frontiers in Drug Discovery

Frontiers Media·Switzerland·ISSN 2674-0338

Open accessIn DOAJFee waivers availableMedicine

Frontiers in Drug Discovery is published by Frontiers Media as an open access journal (ISSN 2674-0338). The list article processing charge is $2,353. Typical time to publication is 15 wks. Its OpenAlex h-index is 19. Primary field: Medicine. It is listed in the Directory of Open Access Journals. Fee waivers are stated as available. Figures on this page are sourced from OpenAlex and DOAJ and should be confirmed on the journal’s own site before submission.

Cost to publish

$2,353

Open-access article processing charge, list price.

Checked · Journal fee page

Time to publication

15 wks

Broadly typical for the field.

h-index

19

OpenAlex citation statistic. Not a Journal Impact Factor.

2-year mean citedness

6.2

Average citations to articles from the previous two years.

What it costs to publish here

Publishing an open-access article in Frontiers in Drug Discovery is listed at $2,353. The publisher also lists 1,950 CHF. The journal reports that fee waivers are available — worth pursuing if you are funding this yourself or working from a lower-income country.

The journal's own fee page →

What this journal has charged over time

List price for an open-access article in Frontiers in Drug Discovery, as recorded by OpenAlex for each year. The fee has risen 24% since 2022, from $1,900 to $2,353.

$0$1.2k$2.4k2022: $1,90020222023: $2,12520232024: $2,12520242025: $2,3532025

Publishers change list prices without notice and often apply discounts, institutional agreements or waivers. Treat this as the trend, and confirm the current figure with the journal.

Peer review and licensing

Review modelAnonymous peer review (policy)
LicenceCC BY
Author keeps copyrightYes
Plagiarism screeningYes
Editorial boardPublished →
LanguagesEN

Verification checks

8 of 8 confirmed

These are facts we could verify in public records, not a verdict. A journal missing a check is not necessarily disreputable — many long-established subscription journals sit outside the open-access registries entirely. Use them as questions to ask, and confirm anything that matters directly with the journal before you submit.

  • Listed in the Directory of Open Access JournalsDOAJ applies a documented set of inclusion criteria.
  • Included in OpenAlex's curated core setOpenAlex flags well-established venues that appear across major indexes.
  • Peer review model publicly declaredAnonymous peer review
  • Publication charges stated up frontA journal that will not tell you the fee before submission is worth a second look.
  • Screens submissions for plagiarismReported to DOAJ by the journal.
  • Participates in a digital preservation schemeArchiving means the record survives if the publisher does not.
  • Assigns persistent identifiers (DOIs)Standard practice; its absence is unusual.
  • Still actively publishingMost recent indexed article: 2026.

Scope

The subjects Frontiers in Drug Discovery publishes most, derived from the topics assigned to its indexed articles.

Computational Drug Discovery MethodsSARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesMonoclonal and Polyclonal Antibodies ResearchMicrobial Natural Products and BiosynthesisCOVID-19 Clinical Research StudiesProtein Degradation and InhibitorsMalaria Research and ControlMachine Learning in Materials SciencePharmacogenetics and Drug Metabolism

Publication record

Indexed articles203
Total citations1,751
i10-index46
Most recent indexed article2026
Open access since2021
All ISSNs2674-0338

Counts reflect what OpenAlex has indexed and will differ from the publisher's own figures. We do not show a founding year: OpenAlex's first-publication dates are distorted by mis-dated records — it puts PLoS ONE in 1806 — and we would rather omit a number than print one we cannot stand behind.